OPEN APP
Home >Markets >Ipo >Ami Organics IPO to open on 1 Sept

Ami Organics IPO to open on 1 Sept

The firm in its DRHP said that it is in consultation with its book running managers for pre-IPO placement of upto Rs100 crore.Intensive Fiscal Services Pvt Ltd, Ambit Pvt Ltd and Axis Capital Ltd are the book running lead managers to the issue. Photo: iStockPremium
The firm in its DRHP said that it is in consultation with its book running managers for pre-IPO placement of upto Rs100 crore.Intensive Fiscal Services Pvt Ltd, Ambit Pvt Ltd and Axis Capital Ltd are the book running lead managers to the issue. Photo: iStock

  • The issue comprises a fresh issue of Rs200 crore and an offer for sale of upto 6.06 million shares by its existing promoters and shareholders

Specialty chemicals maker Ami Organics Ltd’s initial public offering will open on 1 September and close on 3 September.

The issue comprises a fresh issue of 200 crore and an offer for sale of upto 6.06 million shares by its existing promoters and shareholders.
An OFS consist of upto 7 lakh shares by Parul Chetankumar Vaghasia, upto 1.5 lakhs shares by Girishkumar Limbabhai Chovatia, upto 3.05 million shares by Kiranben Girishbhai Chovatia, upto 1.74 lakh shares by Aruna Jayantkumar Pandya
The firm in its DRHP said that it is in consultation with its book running managers for pre-IPO placement of upto 100 crore.
Intensive Fiscal Services Pvt Ltd, Ambit Pvt Ltd and Axis Capital Ltd are the book running lead managers to the issue.
The proceeds from the issue will be used for repayment of financial facilities of upto 140 crore. The firm will also use upto 90 crore for funding working capital requirements. As of March 2021, its net debt stood at 218.73 crore.
For the fiscal year 2021, the company reported a revenue of 340.61 crore versus 239.64 crore a year ago. Net profit for the period stood at 53.99 crore against 27.47 crore last year.
Ami Organics is the leading research and development driven manufacturers of specialty chemicals with varied end usage, focused on the development and manufacturing of advanced pharmaceutical intermediates for regulated and generic active pharmaceutical ingredients and New Chemical Entities and key starting material for agrochemical and fine chemicals, especially from our recent acquisition of the business of Gujarat Organics Ltd.
The firm have developed and commercialised over 450 Pharma Intermediates for APIs across 17 key therapeutic areas since inception and NCE, with a strong focus on R&D across select high-growth high margin therapeutic areas such as anti-retroviral, anti-inflammatory, anti-psychotic, anti-cancer, anti-Parkinson, anti-depressant and anticoagulant, for use across the global pharmaceutical market.
Along with the domestic market, we supply Pharma Intermediates used for manufacturing of APIs and NCEs to various multi-national pharmaceutical companies which cater to the large and fast-growing markets of Europe, China, Japan, Israel, UK, Latin America and the USA.

 

Subscribe to Mint Newsletters
* Enter a valid email
* Thank you for subscribing to our newsletter.

Never miss a story! Stay connected and informed with Mint. Download our App Now!!

Close
×
Edit Profile
My ReadsRedeem a Gift CardLogout